{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:04:37Z","timestamp":1790996677213,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate the value of <jats:sup>123<\/jats:sup>I-2\u03b2-carbomethoxy-3\u03b2-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (<jats:sup>123<\/jats:sup>I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT-SPECT) to change management strategies of patients suspected of parkinsonism.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>This was an institutional review board\u2013approved, retrospective study. DAT-SPECT scans ordered by movement disorder specialist and neurologists from 2011\u20132014 were reviewed. Clinical data and radiological reports of 173 patients suspected of parkinsonism were reviewed. The DAT-SPECT scan results were correlated with clinical assessment and treatment changes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 173 patients (104 male and 69 female subjects; age, 64.4 \u00b1 12.6 years) suspected of parkinsonism were included. Median duration of symptoms was 36 months (range, 1\u2013480 months). Scans were most often requested when there was diagnostic uncertainty in clinical features (59.6%, 103\/173) or to differentiate one other disease from parkinsonism such as Parkinson disease (PD) versus essential tremor (23.7%, 41\/173), PD versus drug-induced parkinsonism (8.7%, 15\/173), or PD versus psychogenic (6.4%, 11\/173) or vascular (1.7%, 3\/173) disorders. Patients were classified, according to the DAT-SPECT scanning results, as those with abnormal DAT-SPECT findings (59%, 102\/173) and those with normal DAT-SPECT findings (41%, 71\/173). In patients with normal DAT-SPECT findings, follow-up management data were available in 76.1% (54\/71). The management changed in 39.4% (28\/54) after DAT scan with starting a new appropriate medications or supportive therapy in 4.2% (3\/28), withholding inappropriate dopaminergic treatment in 11.3% (8\/28), or continuing observation in 23.9% (17\/28). In patients with abnormal DAT-SPECT findings, follow-up management data were available in 78.4% (80\/102). There was change in management of 37.3% (38\/80), a new PD treatment was started in 89.5% (34\/38). The dose of medication was adjusted in 5.3% (2\/38), although the original treatment was not changed. Parkinson disease treatment was stopped in 2.6% (1\/38) and discontinued in 2.6% (1\/38) based on clinical decision of neurologists despite abnormal DAT-SPECT findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>DAT-SPECT findings impacted treatment decisions in 44.7% of patients suspected of Parkinsonism.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002240","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T21:16:54Z","timestamp":1535577414000},"page":"710-714","source":"Crossref","is-referenced-by-count":26,"title":["Impact of DAT-SPECT on Management of Patients Suspected of Parkinsonism"],"prefix":"10.1097","volume":"43","author":[{"given":"Sahar","family":"Mirpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evrim B.","family":"Turkbey","sequence":"additional","affiliation":[{"name":"Russell H Morgan Department of Radiology and Radiological Sciences;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Marashdeh","sequence":"additional","affiliation":[{"name":"Russell H Morgan Department of Radiology and Radiological Sciences;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham","family":"El Khouli","sequence":"additional","affiliation":[{"name":"Russell H Morgan Department of Radiology and Radiological Sciences;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rathan M.","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2353\/ajpath.2007.061011","article-title":"Linking selective vulnerability to cell death mechanisms in Parkinson's disease","volume":"170","year":"2007","journal-title":"Am J Pathol"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.parkreldis.2014.10.022","article-title":"Experience with DaTscan at a tertiary referral center","volume":"21","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mds.22108","article-title":"Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT","volume":"24","year":"2009","journal-title":"Mov Disord"},{"key":"bib4-20230925","first-page":"1224","article-title":"(123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis","volume":"61","year":"2004","journal-title":"Arch Neurol"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V","article-title":"Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group","volume":"15","year":"2000","journal-title":"Mov Disord"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1212\/WNL.42.6.1142","article-title":"What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study","volume":"42","year":"1992","journal-title":"Neurology"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/ageing\/28.2.99","article-title":"Accuracy of diagnosis in patients with presumed Parkinson's disease","volume":"28","year":"1999","journal-title":"Age Ageing"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/mds.20112","article-title":"Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes","volume":"19","year":"2004","journal-title":"Mov Disord"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1212\/WNL.46.1.231","article-title":"[123I] beta-CIT\/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease","volume":"46","year":"1996","journal-title":"Neurology"},{"key":"bib11-20230925","first-page":"1540","article-title":"Parkinson Study Group","volume":"55","year":"2000","journal-title":"Neurology"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jnnp-2011-301695","article-title":"Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study","volume":"83","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/mds.10482","article-title":"Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations","volume":"18","year":"2003","journal-title":"Mov Disord"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1471-4159.1991.tb02580.x","article-title":"The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus","volume":"56","year":"1991","journal-title":"J Neurochem"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00259-008-0777-2","article-title":"The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism","volume":"35","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000370116","article-title":"Is there a role for DAT-SPECT imaging in a specialty movement disorders practice?","volume":"15","year":"2015","journal-title":"Neurodegener Dis"},{"key":"bib17-20230925","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s00259-010-1520-3","article-title":"Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/MNM.0b013e328364aa2e","article-title":"123I-FP-CIT and 123I-IBZM SPECT uptake in a prospective normal material analysed with two different semiquantitative image evaluation tools","volume":"34","year":"2013","journal-title":"Nucl Med Commun"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2967\/jnumed.111.100784","article-title":"SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0","volume":"53","year":"2012","journal-title":"J Nucl Med"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00702-016-1586-6","article-title":"Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism","volume":"123","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"key":"bib21-20230925","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","article-title":"Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis","volume":"86","year":"2016","journal-title":"Neurology"},{"key":"bib22-20230925","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/WNL.0b013e31826e25ce","article-title":"Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort","volume":"79","year":"2012","journal-title":"Neurology"},{"key":"bib23-20230925","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2967\/jnumed.114.148619","article-title":"Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib24-20230925","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/ncpneuro0986","article-title":"Radionuclide scanning to diagnose Parkinson disease: is it cost-effective?","volume":"5","year":"2009","journal-title":"Nat Clin Pract Neurol"},{"key":"bib25-20230925","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1093\/brain\/awr177","article-title":"The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration","volume":"134","year":"2011","journal-title":"Brain"},{"issue":"Suppl 3","key":"bib26-20230925","first-page":"S425","article-title":"SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease","volume":"13","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"bib27-20230925","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.108.059998","article-title":"Imaging approaches to Parkinson disease","volume":"51","year":"2010","journal-title":"J Nucl Med"},{"key":"bib28-20230925","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1399-0004.2012.01901.x","article-title":"Exome sequencing overrides formal genetics: ASPM mutations in a case study of apparent X-linked microcephalic intellectual deficit","volume":"83","year":"2013","journal-title":"Clin Genet"},{"key":"bib29-20230925","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/01.mnm.0000243374.11260.5b","article-title":"Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging","volume":"27","year":"2006","journal-title":"Nucl Med Commun"},{"key":"bib30-20230925","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/RLU.0000000000000766","article-title":"The impact of DaTscan in the diagnosis of Parkinson disease","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib31-20230925","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.0b013e3182494c72","article-title":"To scan or not to scan: DaT is the question","volume":"78","year":"2012","journal-title":"Neurology"},{"key":"bib32-20230925","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1212\/WNL.0b013e318248e520","article-title":"Role of DaTSCAN and clinical diagnosis in Parkinson disease","volume":"78","year":"2012","journal-title":"Neurology"},{"key":"bib33-20230925","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00259-002-0938-7","article-title":"Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand","volume":"29","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib34-20230925","first-page":"3","article-title":"Dopamine transporter imaging in psychogenic parkinsonism and neurodegenerative parkinsonism with psychogenic overlay: a report of three cases","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"Suppl 2","key":"bib35-20230925","first-page":"27","article-title":"Diagnosis and initiation of treatment in Parkinson's disease","volume":"121","year":"2011","journal-title":"Int J Neurosci"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003072-201810000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:09:40Z","timestamp":1695618580000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201810000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002240","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}